A six-year experience of catheter-related bloodstream infections in hemodialysis patients
The Journal of Infection in Developing Countries · 30.06.2026 · 20 (06) · 869-877
DOI: 10.3855/jidc.22212 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, online erschienen am 30.06.2026. Verfasst von Zeynep Ture und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Private Gurlife Hospital, Eskişehir, Türkiye. Hauptthemen laut MEDLINE: Catheter-Related Infections, Renal Dialysis, Bacteremia. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
This study investigated the clinical characteristics, causative microorganisms, and antibiotic resistance patterns of catheter-related bloodstream infections (CRBSIs) in hemodialysis patients at a tertiary healthcare institution. Methodology: A retrospective analysis of 300 patients treated for CRBSIs between January 2018 and December 2023 was conducted. Patients were divided into two groups: those with less than 1 year of hemodialysis (Group 1) and those with more than 1 year of hemodialysis (Group 2). Risk factors for intensive care unit (ICU) transfer and 28-day mortality were analyzed.
Results
The median age was 68 years. Gram-positive bacteria were the predominant pathogens (69%), with Staphylococcus aureus being the most frequent. Group 1 had significantly higher rates of recent hospitalization (p = 0.014) and a history of previous ICU admission (p = 0.001). However, no significant differences were found in causative microorganisms or antimicrobial resistance between the two groups. Risk factors for ICU transfer included carbapenem resistance (OR: 7.657, p = 0.013), history of catheter revision (OR: 4.632, p = 0.022), and leukocytosis (OR: 1.150, p = 0.004). The 28-day mortality rate was 8%. Significant risk factors for mortality were ICU transfer (OR: 17.29; p = 0.001) and Vancomycin-Resistant Enterococcus (VRE) infection (OR: 14.10; p = 0.002).
Conclusions
Despite shorter-term dialysis patients having more frequent hospitalizations, the distribution and resistance of pathogens remain similar regardless of hemodialysis duration. Empirical therapy should prioritize broad anti-staphylococcal coverage and be tailored to specific risk factors such as VRE or carbapenem resistance rather than hemodialysis duration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Private Gurlife Hospital, Eskişehir, Türkiye.
- Department of Internal Medicine, University of Health Science, Kayseri City Hospital, Kayseri, Türkiye.
- Department of Internal Medicine, Erciyes University, Kayseri, Türkiye.
- Department of Infectious Diseases and Clinical Microbiology, Erciyes University, Kayseri, Türkiye.
- Department of Clinical Bacteriology and Infectious Diseases, Preventing Hospital Infections Doctorate Programme, Institute of Health Sciences, Erciyes University, Kayseri, Türkiye.
- Department of Nephrology, Erciyes University, Kayseri, Türkiye.
Zitieren
APA
Ture, Z., Demiray, A., Demirkutlu, K., Hayırlıdağ, B., Cevahir, F., & Koçyiğit, İ. (2026). A six-year experience of catheter-related bloodstream infections in hemodialysis patients. The Journal of Infection in Developing Countries, 20(06), 869-877. https://doi.org/10.3855/jidc.22212
Vancouver
Ture Z, Demiray A, Demirkutlu K, Hayırlıdağ B, Cevahir F, Koçyiğit İ. A six-year experience of catheter-related bloodstream infections in hemodialysis patients. The Journal of Infection in Developing Countries. 2026;20(06):869-877. doi:10.3855/jidc.22212
BibTeX
@article{Ture2026,
author = {Ture, Zeynep and Demiray, Alparslan and Demirkutlu, Kadir and Hayırlıdağ, Beyza and Cevahir, Fatma and Koçyiğit, İsmail},
title = {A six-year experience of catheter-related bloodstream infections in hemodialysis patients},
journal = {The Journal of Infection in Developing Countries},
year = {2026},
volume = {20},
number = {06},
pages = {869--877},
doi = {10.3855/jidc.22212}
}
EUVIMED